SER Stock Forecast: Serina Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.12
−6.67% on the day

The median 12-month analyst price target for Serina Therapeutics, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$29.8M
Ticker Nerd rank
18/ 100
Median analyst target
$9.50
Analysts covering
2
Revenue$0.0
Operating income−$6.8M
Net income−$6.4M
Free cash flow−$6.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.4%
1M
−32.5%
YTD
−41.5%
1Y
−70.2%
From 52W high
−73.7%
From 52W low
0.0%
$1.12
$4.26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Serina Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
52
Revisions
50
Accruals
50
Value
28
Momentum
26
Quality
17
Issuance
14
Growth
10

Volatility (52): The share price has been relatively steady.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26SERHigh $11.00Median $9.50Low $8.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$8.00
Low
$9.50
Median
$11.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Oct 2026BTIGReiteratesBuy—
10 Sept 2026BTIGReiteratesBuy—
1 July 2026BTIGInitiatesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
14 July 2025HC Wainwright & Co.InitiatesBuy—
11 Mar 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SER.

Market Radar

This page is one stock. Monday covers all of them.

SER appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SER vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Serina Therapeutics, Inc. returned −70.2% against +6.9% for the S&P 500, dividends included.

SER vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26SERS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
238.1×

Cheaper than 2% of US stocks

Price / book
2.1×

Cheaper than 41% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−315.8%

Higher than 5% of US stocks

Return on assets
−98.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Serina Therapeutics, Inc. has a market value of $29.8M and an enterprise value of $13.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.2M.

  • Free cash flow in the twelve months to 30 June 2026: −$21.2M.

  • Shares outstanding: 15.0M.

  • Serina Therapeutics, Inc. employs 16 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SER and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SERSerina Therapeutics, Inc.$29.8M18
PMNProMIS Neurosciences, Inc.$28.3M30
RNTXRein Therapeutics, Inc.$28.8M39
NNVCNanoViricides, Inc.$29.0M52
NXTCNextCure, Inc.$29.5M43
EDSAEdesa Biotech, Inc.$27.0M49
EXOZeXoZymes, Inc.$27.0M11

Take a look at SER’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Serina Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SER

What is the SER stock price forecast for 2026-2027?

The median 12-month analyst price target for Serina Therapeutics, Inc. is $9.5, with estimates ranging from $8 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SER stock a buy right now?

Of the 2 analysts covering Serina Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Serina Therapeutics, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SER?

As at 21 Nov 2026, Serina Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (52 of 100).

Will SER stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $9.5, and Ticker Nerd's factor model ranks Serina Therapeutics, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SER stock forecast for 2030?

No analyst covering Serina Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $11 over the next 12 months.

How has SER stock performed over the past year?

Serina Therapeutics, Inc. returned -70.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Serina Therapeutics, Inc. do?

Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates.

Company

About Serina Therapeutics, Inc.

Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates. Serina Therapeutics Inc. is advancing a pipeline of wholly owned product candidates aimed primarily at central nervous system disorders, including Parkinson’s disease, along with programs in pain and other therapeutic areas. Its current business is centered on research, preclinical development, and clinical evaluation of drug candidates built around its platform technology. Based in Huntsville, Alabama, Serina Therapeutics Inc. plays a specialized role in the biotechnology market by combining materials science with drug development to address treatment challenges in difficult-to-deliver therapies.

CEO Mr. Steven A. Ledger · 16 employees · United States · https://www.serinatx.com